Molbio Diagnostics Ltd.
MOLBIOMainboard
Ask Iris
Overview
Molbio Diagnostics Limited is an India-based point-of-care diagnostics company that develops and sells the Truenat portable, battery-operated real-time PCR platform and disease-specific test kits for rapid molecular testing of infectious and non-communicable diseases. The company combines in-house R&D (through its subsidiary Bigtec) with manufacturing in India and sells globally to public health programs, labs, and hospitals; it has also expanded into adjacent diagnostics workflows through radiology (via Prognosys) and digital pathology (via OptraScan investments).
Opening Date
Aug 10, 2026
Closing Date
Aug 12, 2026
Listing Date
Aug 17, 2026
IPO Type
Mainboard
IPO Status
Closed
Issue Size
939.7 Cr
Fresh Issue
200 Cr
Offer for Sale
739.7 Cr
Price Band
₹768 - ₹807
Lot Size
18
IPO Timeline
Financials
Revenue
Profit After Tax (PAT)
Use of IPO funds
Key Performance Indicator
P/E Ratio
55.43
EPS
14.56
ROE
15.59%
ROCE
17.55%
RONW
14.55%
Debt to Equity Ratio
0.36
PAT Margin
11.28%
EBITDA Margin
22.56%
P/B
9.55
Bull vs Bear
Bull case
- •
The business is built around a device plus test-kit ecosystem, so every installed device can drive repeat kit purchases, supporting steadier long-term cash generation.
- •
Strong IP and long R&D cycle create real entry barriers; it’s harder for new players to copy the platform and win government approvals quickly.
- •
Point-of-care testing is gaining acceptance, and this platform works in low-infrastructure settings, expanding where molecular testing can reach.
Bear case
- •
Customer concentration is extreme: 84.56% of product revenue is from governments and aid agencies. Policy shifts, tender losses, or funding cuts can hit sales hard.
- •
TB dominates demand: 70.20% of product revenue and 96.02% of kit units are TB-related. Any shift in TB testing approach can pressure growth.
- •
R&D spending is ongoing, but commercialised output is limited. If new tests don’t get approvals or adoption, costs rise without matching revenue.
Net takeaway
The long-term story is a point-of-care diagnostics platform that can create repeat demand through test kits and is protected by meaningful IP, so it can scale with wider testing access. But the business is heavily tied to government tenders and TB programs, so a single policy or product-mix change can affect revenue and cash flows. The main thing to monitor over time is diversification—how much revenue shifts away from TB and from a few government buyers.
